• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units.

作者信息

Toffart Anne-Claire, Dhalluin Xavier, Girard Nicolas, Chouaid Christos, Audigier-Valette Clarisse, Duruisseaux Michaël, Mennecier Bertrand, Parrot Antoine, Fournel Pierre, Moro-Sibilot Denis, Timsit Jean-François

机构信息

Grenoble University 1 U 823, A Bonniot Institute, J Fourier University, Rond-point de la Chantourne, 38706, La Tronche Cedex, France,

出版信息

Intensive Care Med. 2015 Jan;41(1):164-5. doi: 10.1007/s00134-014-3535-x. Epub 2014 Nov 4.

DOI:10.1007/s00134-014-3535-x
PMID:25366122
Abstract
摘要

相似文献

1
Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units.患有致癌突变的晚期肺癌患者应入住重症监护病房。
Intensive Care Med. 2015 Jan;41(1):164-5. doi: 10.1007/s00134-014-3535-x. Epub 2014 Nov 4.
2
Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.非小细胞肺癌患者同时存在 EGFR、ALK、ROS1、KRAS 或 BRAF 突变的临床特征和治疗选择。
Cancer Med. 2019 Jun;8(6):2858-2866. doi: 10.1002/cam4.2183. Epub 2019 Apr 24.
3
Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.不同临床分期非小细胞肺癌患者中的致癌驱动基因突变。
Ann Oncol. 2013 May;24(5):1319-25. doi: 10.1093/annonc/mds626. Epub 2012 Dec 30.
4
Detection of E2A-PBX1 fusion transcripts in human non-small-cell lung cancer.检测人非小细胞肺癌中的 E2A-PBX1 融合转录本。
J Exp Clin Cancer Res. 2013 May 20;32(1):29. doi: 10.1186/1756-9966-32-29.
5
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by Fusions.MAPK 通路改变与融合驱动的肺癌患者不良生存相关，并导致对治疗的耐药性。
Clin Cancer Res. 2020 Jun 15;26(12):2932-2945. doi: 10.1158/1078-0432.CCR-19-3321. Epub 2020 Mar 2.
6
Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?免疫疗法治疗致癌驱动的晚期非小细胞肺癌：是否是时候改变了？
Cancer Treat Rev. 2018 Dec;71:47-58. doi: 10.1016/j.ctrv.2018.10.006. Epub 2018 Oct 15.
7
Predictive markers in lung cancer: a few hints for the practicing pathologist.肺癌中的预测性标志物：给执业病理学家的一些提示。
Pathologica. 2018 Mar;110(1):29-38.
8
Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.ROS1 重排非小细胞肺癌患者中不同类型 ROS1 融合伙伴的克唑替尼疗效。
J Thorac Oncol. 2018 Jul;13(7):987-995. doi: 10.1016/j.jtho.2018.04.016. Epub 2018 Apr 25.
9
Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.培美曲塞为基础的化疗在 ROS1 融合阳性肺腺癌患者中的疗效与东亚人群中携带其他驱动基因突变患者的疗效比较。
J Thorac Oncol. 2016 Jul;11(7):1140-52. doi: 10.1016/j.jtho.2016.03.022. Epub 2016 Apr 16.
10
High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.非小细胞肺癌伴同步多发磨玻璃肺结节患者的驱动基因突变差异较大。
J Thorac Oncol. 2015 May;10(5):778-783. doi: 10.1097/JTO.0000000000000487.

引用本文的文献

1
Severe hemoptysis associated with lung cancer in the ICU: recurrence and outcome.重症监护病房中与肺癌相关的严重咯血：复发与结局
Ann Intensive Care. 2025 Mar 20;15(1):33. doi: 10.1186/s13613-025-01421-7.
2
[Palliative aspects in clinical acute and emergency medicine as well as intensive care medicine : Consensus paper of the DGIIN, DGK, DGP, DGHO, DGfN, DGNI, DGG, DGAI, DGINA and DG Palliativmedizin].[临床急性与急诊医学以及重症监护医学中的姑息治疗方面：德国内科与急诊医学学会、德国麻醉医师学会、德国病理学会、德国医院医师学会、德国营养学会、德国神经重症监护与急诊医学学会、德国胃肠病学会、德国麻醉与重症监护医学学会、德国介入与麻醉重症监护医学学会以及德国姑息医学学会的共识文件]
Med Klin Intensivmed Notfmed. 2023 Dec;118(Suppl 1):14-38. doi: 10.1007/s00063-023-01016-9. Epub 2023 Jun 7.
3

本文引用的文献

1
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.克唑替尼与化疗用于治疗晚期 ALK 阳性肺癌。
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.
2
Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer.ALK 阳性非小细胞肺癌机械通气患者使用克唑替尼治疗获得成功。
J Thorac Oncol. 2013 Feb;8(2):250-3. doi: 10.1097/JTO.0b013e3182746772.
3
Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation.
Prognostic factors for advanced lung cancer patients with do-not-intubate order in intensive care unit: a retrospective study.
重症监护病房中拒绝插管的晚期肺癌患者的预后因素：一项回顾性研究。
BMC Pulm Med. 2022 Jun 24;22(1):245. doi: 10.1186/s12890-022-02042-7.
4
Patterns of ICU admissions and outcomes in patients with solid malignancies over the revolution of cancer treatment.在癌症治疗变革过程中实体恶性肿瘤患者的重症监护病房（ICU）收治模式及治疗结果
Ann Intensive Care. 2021 Dec 24;11(1):182. doi: 10.1186/s13613-021-00968-5.
5
Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation.酪氨酸激酶抑制剂改善了接受机械通气的重症表皮生长因子受体突变型肺癌患者的生存率。
Biomedicines. 2021 Oct 8;9(10):1416. doi: 10.3390/biomedicines9101416.
6
[Not Available].[无可用内容]
Rev Malad Respir Actual. 2021 Sep;13(2):2S244-2S251. doi: 10.1016/S1877-1203(21)00116-6. Epub 2021 Oct 11.
7
Etiologies of delayed diagnosis and six-month outcome of patients with newly diagnosed advanced lung cancer with respiratory failure at initial presentation.新发呼吸衰竭的晚期肺癌患者延迟诊断的病因和六个月的预后。
Thorac Cancer. 2020 Sep;11(9):2672-2680. doi: 10.1111/1759-7714.13604. Epub 2020 Aug 6.
8
The Intensive Care Medicine research agenda on critically ill oncology and hematology patients.重症肿瘤和血液学患者的重症监护医学研究议程。
Intensive Care Med. 2017 Sep;43(9):1366-1382. doi: 10.1007/s00134-017-4884-z. Epub 2017 Jul 19.
9
Focus on immunocompromised patients.
Intensive Care Med. 2017 Sep;43(9):1415-1417. doi: 10.1007/s00134-017-4857-2. Epub 2017 Jun 9.
10
Lazarus response to treatment of patients with lung cancer and oncogenic mutations in the intensive care unit.重症监护病房中肺癌及致癌基因突变患者对治疗的拉撒路反应
J Thorac Dis. 2016 Nov;8(11):E1455-E1461. doi: 10.21037/jtd.2016.11.110.
J Thorac Oncol. 2013 Jan;8(1):e1-2. doi: 10.1097/JTO.0b013e3182762812.
4
Use of intensive care in patients with nonresectable lung cancer.非手术治疗肺癌患者的重症监护使用。
Chest. 2011 Jan;139(1):101-8. doi: 10.1378/chest.09-2863. Epub 2010 Jul 15.
5
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.吉非替尼或化疗用于治疗具有突变型 EGFR 的非小细胞肺癌。
N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.